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BACKGROUND: Favourable outcomes of breast cancer screening trials in the 1970s and 1980s resulted in the launch of population-
based service screening programmes in many Western countries. We investigated whether improvements in mammography and
treatment modalities have had an influence on the effectiveness of breast cancer screening from 1975 to 2008.
METHODS: In Nijmegen, the Netherlands, 55529 women received an invitation for screening between 1975 and 2008. We designed a
case–referent study to evaluate the impact of mammographic screening on breast cancer mortality over time from 1975 to 2008.
A total number of 282 breast cancer deaths were identified, and 1410 referents aged 50–69 were sampled from the population
invited for screening. We estimated the effectiveness by calculating the odds ratio (OR) indicating the breast cancer death rate for
screened vs unscreened women.
RESULTS: The breast cancer death rate in the screened group over the complete period was 35% lower than in the unscreened group
(OR¼0.65; 95% CI¼0.49–0.87). Analysis by calendar year showed an increasing effectiveness from a 28% reduction in breast
cancer mortality in the period 1975–1991 (OR¼0.72; 95% CI¼0.47–1.09) to 65% in the period 1992–2008 (OR¼0.35; 95%
CI¼0.19–0.64).
CONCLUSION: Our results show an increasingly strong reduction in breast cancer mortality over time because of mammographic screening.
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Breast cancer screening trials conducted in the 1970s and 1980s
demonstrated a 20–30% reduction in breast cancer mortality for
women aged 50–69 (Nelson et al, 2009). On the basis of these trial
results, service screening programmes for breast cancer were
implemented on a large scale in Europe, North America and
Australia in the 1990s (Shapiro et al, 1998). Subsequent evaluations
of these programmes have shown a beneficial effect on breast
cancer mortality, which has been comparable with the trial
outcomes (Demissie et al, 1998; Gabe and Duffy, 2005).
Since the trial era and the start of service screening, major
advances have been made in the detection and treatment of breast
cancer (Early Breast Cancer Trialists’ Collaborative Group, 2005;
Yaffe et al, 2008). The complete screening chain, from the technical
aspects of mammography to the training and experience of
radiographers and radiologists has improved. In addition, since
the 1980s there has been a growing use of adjuvant therapy. No
study has yet evaluated the influence of screening on breast cancer
mortality taking into account the developments in screening
performance and treatment over time.
Trends show a decline in breast cancer mortality. Some
investigators have attributed this to screening and improved
treatment (Levi et al, 2005; He ´ry et al, 2008; Otten et al, 2008;
Autier et al, 2010), while others suggested that screening was not
relevant (Zahl and Maehlen, 2005; Becker et al, 2007; Jorgensen
et al, 2010). Although useful and important, the analysis of trends
in breast cancer mortality should be interpreted with caution for
inference on causal relations. Breast cancer mortality is also
declining in age groups not invited for screening and in countries
without a national screening programme (Autier et al, 2010).
To achieve a reliable assessment of the effect of screening on
mortality, it is necessary to make a direct link between a woman’s
cause of death and her screening history (Verbeek and Broeders,
2010). Data from long-running screening programmes are limited,
except in Nijmegen, the Netherlands, where a programme for
breast cancer service screening was started in 1975 (Holland et al,
2007). Between then and 2008, 405131 invitations were sent to
55529 women aged 35 years and older.
We have used data from this ongoing programme to investigate the
impact of screening on breast cancer mortality between 1975 and 2008.
MATERIALS AND METHODS
Setting
We designed our study based on the population of women invited
to the service screening programme in Nijmegen, the Netherlands.
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sIn 1975, this programme started inviting women aged 35 years
and over for a biennial mammographic screening examination.
In 1989, at the start of the national screening programme, the age
of invitation was gradually adapted to that of the national policy,
which at that time was 50–69 years until 1997, and 50–74 years
from 1998 onwards. More than 257300 screening examinations
were performed up to 2008. The screening examination consisted
of a two-view mammogram (a mediolateral oblique and cranio-
caudal view) in initial screens. In subsequent screenings, the
mediolateral oblique view is standard. Additional craniocaudal
views are performed only on indication, for example, dense
glandular tissue, implants and whenever abnormalities are
suspected by the radiographer. At present, craniocaudal view is
conducted in about 50% of the women during subsequent
examination. A detailed description of the programme has been
published (Otten et al, 1996).
A separate registry holds information on all patients with breast
cancer in Nijmegen diagnosed within and outside the screening
programme. Vital status was obtained from the Municipal Personal
Records Data Base (GBA) up to and including 2008. Assessments
of causes of death were made by a committee of physicians
comprising a pathologist, medical oncologist and a radiologist.
The committee members were unaware of the screening history.
Both our screening and patient datasets are registered with the
Netherlands Data Protection Authority.
Study design and study population
We applied a case–referent design (Verbeek and Broeders, 2010)
to evaluate the effect of mammographic screening on breast cancer
mortality by calendar year of invitation. Previous evaluations of
screening have used the case–control design (Gabe and Duffy,
2005). We prefer the term case–referent study to case–control
study in this context because the uptake of screening in the case
group of breast cancer deaths is referred to the probability of
having been screened in the population from which the cases
originate. The lack of overlap in the age groups over calendar time
prompted us to restrict the study population to women aged 50–69
at invitation.
In the case series of breast cancer deaths, we ascertained
whether women were screened or not screened before breast
cancer diagnosis, and calculated the odds of having been screened
in this period. To interpret the screening odds in the case
group, we also calculated the screening odds in a reference group.
For each case, five referents were randomly sampled from the
population of women invited for screening. Referents had to be
eligible for screening, they did not have breast cancer at the time of
invitation and were living in Nijmegen at the time of death of the
case. This type of sampling follows the principle of incidence
density sampling (Miettinen, 1976; Greenland and Thomas, 1982).
The purpose of the case–referent design is to arrive at a valid
estimate of the breast cancer mortality rate in both the screened
and unscreened population.
Relevant time frame for screening
Screening can only be effective if the examination is performed in
the period that breast cancer is developing and potentially
detectable by the screening test before symptoms appear (Weiss
et al, 1992; Broeders and Verbeek, 2005). The duration of the
detectable preclinical period is unknown at the individual level;
based on estimates of lead time for breast cancer (Weiss et al, 1992;
Broeders and Verbeek, 2005) we have set the time frame for
screening invitation at a 4-year period before breast cancer
diagnosis of the case. In a biennial screening schedule, this period
includes two consecutive invitations, that is, the index-invitation
(the most recent invitation before diagnosis of the case) and
the screening preceding the index. The year of index-invitation is
the calendar year of the date of the invitation to the index-
screening. The age at index-invitation is the age at this point in
time. Both cases and referents have had the same opportunity for
screening; therefore exposure to screening is defined as having
been screened or not in the 4-year period.
As a result of this 4-year time frame and the constant
participation in our programme, there are equal numbers of
initial and subsequent screening examinations in our study
population over time.
Analysis
To estimate the effect of screening on breast cancer mortality, we
calculated the odds ratio (OR), using logistic regression techniques
(Rothman et al, 2008). The OR is the odds of having been screened
vs not screened in the case series of breast cancer deaths,
compared with the odds in the reference group from which the
cases theoretically originate. As such, the OR is the breast cancer
mortality in screened women divided by the breast cancer
mortality in unscreened women (Miettinen, 1976).
First, the OR was calculated for the entire screening era from
1975 through 2008. Second, we calculated the ORs in the calendar
periods 1975–1991 and 1992–2008. In order to make sure that
the two groups were followed for an equal amount of time,
we restricted this part of the analysis to cases who died within
the same calendar period. Finally, the effect by calendar year
(continuous variable) at index-invitation was assessed by includ-
ing an interaction term, the combination of screening and calendar
year, in the logistic regression model. We corrected the ORs for the
confounding influence of age at index-invitation by stratification
into 5-year age groups. SAS 9.2 software (SAS Institute Inc.,
Cary, NC, USA) was used for the analysis.
RESULTS
Characteristics of the study population
Between 1975 and 2008, a total number of 282 breast cancer
deaths were identified. We randomly sampled 1410 referents from
the population invited for screening in the same period.
The median age at index-invitation in the case group was 59
(interquartile range 54–64) and 57 (interquartile range 53–62) in
the reference group.
Screening effect
Over the entire screening period from 1975 to 2008, 191 cases were
screened and 91 not screened, 1089 referents were screened and
321 not screened. After correction for the confounding influence of
age at invitation, the screened women experienced a 35% lower
breast cancer mortality rate compared with unscreened women
(OR¼0.65; 95% CI¼0.49–0.87; Table 1).
Impact of calendar period
Among women invited between 1975 and 1991, screening
prevented 28% of the otherwise prevailing breast cancer mortality
(OR¼0.72; 95% CI¼0.47–1.09; Table 1). In the period 1992–
2008, the breast cancer mortality was 65% lower in screened
women compared with unscreened women (OR¼0.35; 95%
CI¼0.19–0.64); P-value for the interaction between period and
screening effect¼0.04.
Detailed analysis of the influence of calendar year of invitation
showed a trend of increasing effectiveness of breast cancer
screening over time (1975–2008) (Figure 1); P-value for inter-
action¼0.02.
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sDISCUSSION
The results of our study show an increase in impact of
mammographic service screening on the prevention of breast
cancer death over time. There are a number of possible
explanations for this increase in effectiveness. There have been
significant improvements in mammographic screening and treat-
ment over the last 30 years. However, methodological issues
(confounding- and self-selection bias) may have influenced our
results. We will discuss each of these points consecutively.
First, we believe that improvements in the quality of service
screening (Hendrick et al, 2002; Yaffe et al, 2008; Ichikawa et al,
2010), that is, progressions in quality assurance, training of
radiographers and radiologists and advances in mammography
techniques, have had an effect on the growing benefit of screening.
The introduction of an anti-scatter grid for mammography, a
radiation exposure dispenser, the daylight system and improve-
ments towards smaller focal spots have led to higher image quality
with less radiation exposure (Yaffe et al, 2008).
Second, multidisciplinary teams have been working on the
assessment of recalled women and treatment of patients since the
start of the screening programme (Holland et al, 2007). Improve-
ments in breast cancer treatment during the course of our study
period have also resulted in a greater combined benefit of early
detection and treatment. Since the 1970s, the use of chemotherapy
and hormonal therapy after surgery has increased. In the
Netherlands, this occurred predominantly between 1975 and
1990 (Vervoort et al, 2004). A meta-analysis has shown that
adjuvant treatment of early stage breast cancer reduces breast
cancer mortality (Early Breast Cancer Trialists’ Collaborative
Group, 2005). This overview indicates that chemotherapy at an
early stage of the disease reduced breast cancer mortality by 20%
in women aged 50–69. Furthermore, in patients with oestrogen
receptor positive breast cancer, chemotherapy followed by
tamoxifen or the use of tamoxifen alone caused an even greater
breast cancer mortality reduction: about 31%. The success of
adjuvant treatment for early stage breast cancer emphasises the
importance of the synergy between early detection and early
treatment (Berry et al, 2005).
Third, confounding bias could have had a role in our results, but
we believe its influence on our effect estimates is marginal. The
anticipated strong relation between a woman’s age and the
occurrence of breast cancer death, and the age-related participa-
tion in our screening programme, prompted us to correct for age
at invitation.
We considered to what extent residual confounding bias
remains after having addressed the influence of age. One candidate
may be mammographic density, which in itself is an important risk
factor for breast cancer (Boyd et al, 2007). However, the strong
specific mammographic appearance composed of 475% of
glandular tissue and stroma is only prevalent in about 5% of the
post-menopausal women (Pisano et al, 2005). A correction for age
also implies an indirect correction for mammographic density,
because of the high correlation between mammographic density
and age (Groenwold et al, 2010).
Other risk factors for breast cancer like obesity, socioeconomic
status, nulliparity, late age at menopause, early age at menarche
and family history show a 1.5–4-fold relative risk of breast cancer
at most (Amir et al, 2010). Using sensitivity analysis (Schlesselman,
1978) we developed realistic scenarios of prevalence and strength
of these risk factors on screened and not screened groups, and
explored the impact of residual confounding bias. The results
confirmed that a correction for residual confounding beyond age
caused by these factors does not produce a major shift in our
estimated OR. For instance, if a risk factor or risk profile with a
relative risk of four is present in 10% of the screened women
compared with 20% in the unscreened women, then our apparent
OR of 0.35 would be adjusted to 0.43. Our effect estimate will only
weaken in an extreme situation where a combination of strong risk
factors is much less present among screened women compared
with unscreened women.
Finally, related to the issue of confounding, is bias because of
self-selection. Mammographic screening may seem more effective
than it in fact is if women who participate in screening
programmes have a lower background risk of dying from breast
cancer. In the literature, contradictory results have been noted
with regard to the direction and magnitude of self-selection bias.
Where Friedman and Dubin (1991) found that screened women
were at higher baseline risk for breast cancer death, Moss (1991)
found the opposite.
To obtain a fair estimate of the amount of self-selection, the
ratio of the breast cancer death among not-invited women and
non-participants has to be calculated (Duffy et al, 2002). In our
study, we were not able to calculate an estimate for self-selection,
as we did not have an uninvited group for the main part of our
study period. Nevertheless, we have two reasons for believing that
the influence of self-selection bias in our results was only minor.
First, during the early years, Verbeek et al (1984) performed a
geographical comparison on breast cancer incidence rates and
found no evidence of self-selection bias. Second, recently we (Paap
et al, 2010a) quantified the extent of self-selection bias for a region
close to Nijmegen. The resulting correction factor of 0.84 (95%
CI¼0.58–1.21) indicates a lower background risk in women who
do not attend screening. When we applied this factor to the
formula described by Duffy et al (2002), our OR of 0.35 changed to
0.28. Since both studies showed no major influence of self-
selection bias and because we had a constant participation rate in
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Figure 1 The OR of breast cancer death for screened vs unscreened
women invited in the period 1975–2008. The line represents the OR
along the continuum of calendar year of screening invitation; the dotted
lines represent the 95% confidence interval.
Table 1 The effectiveness of mammographic screening on breast cancer
mortality expressed by odds ratios, according to calendar period of index-
invitation at screening and corrected for age at invitation
Calendar period of
index-invitation
Cases screened
(unscreened)
Referents screened
(unscreened)
Odds ratio
(95% CI)
1975–2008 191 (91) 1089 (321) 0.65 (0.49–0.87)
1975–1991 90 (40) 501 (149) 0.72 (0.47–1.09)
1992–2008 29 (23) 202 (58) 0.35 (0.19–0.64)
Abbreviation: CI¼confidence interval.
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sour programme, we expect no change in the amount of this bias
over time.
In the literature many different estimates on the preventive
effect of breast cancer screening have been published. It is
important to consider that study design and method of analysis
contribute greatly to these differences. More than two decades ago,
trials were performed in a ‘laboratory’ setting, whereas cohort and
case–referent designs are used to evaluate real-life current
screening practice. In trials, non-compliance in the invitation
arm, and contamination, that is, screening examination in the
control (not invited) arm cause an underestimation of the actual
screening effect (Demissie et al, 1998). In cohort studies,
differences in trends of breast cancer mortality are compared for
screened and unscreened groups. A recent study on the Norwegian
screening programme reported, after an average follow-up of 2.2
years, a seemingly disappointing 10% breast cancer mortality
reduction because of screening (Kalager et al, 2010). On the basis
of the diverging trends in mortality over time, as was demon-
strated in a study from Sweden showing a 14% mortality reduction
after 10 years in the age group 40–49 (Jonsson et al, 2000), and a
29% reduction after 16 years (Hellquist et al, 2011), the Norwegian
results can actually be regarded as very promising.
In comparison with cohort studies, the case–referent design
does not allow for estimating relative or absolute risks in breast
cancer mortality. The advantage of the case–referent approach is
that it directly links a woman’s cause of death with her screening
history. Therefore, we can accurately estimate the OR of screened
vs unscreened women in the relevant time frame of screening
invitation during the detectable preclinical period. As such, the OR
is the mortality in screened vs not screened women. Case–referent
studies from the England, Italy and Iceland, where screening
started in the 1990s, showed a mortality reduction ranging from 41
to 65% (Gabe et al, 2007; Allgood et al, 2008; Puliti et al, 2008). In
general, the design used in these studies is similar to ours (Paap
et al, 2010b). The strength of our study is that we investigated
temporal trends in screening effectiveness over time between 1975
and 2008.
In conclusion, we report on a strong and steady increase in the
effectiveness of service screening on breast cancer mortality across
the period 1975–2008, resulting in a 65% breast cancer mortality
reduction in 1992–2008 compared with a 28% reduction in
1975–1991. Our findings demonstrate that mammographic screen-
ing has become more effective over time.
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